Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Workiva Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Workiva Inc trades at $72.22 (market cap $3.95B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 2.2× Workiva Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Workiva Inc for 20 Days on average.
| KYMR | WK | |
|---|---|---|
Market Cap | $8.87B | $3.95B |
Volume | 779,107 | 612,757 |
Sector | Health | Technology |
52-Week High | $127.31 | $93.31 |
52-Week Low | $55.80 | $44.31 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $8.26B | $3.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WK trades at $72.50, down 0.74% on the day, with strong technical momentum showing bullish moving averages and support at $72. The company demonstrates robust revenue growth, reaching $966M in 2026 with net income turning positive at $47M, while consistently beating earnings expectations. Recent product innovations in AI and regulatory technology highlight ongoing business development.
The outlook remains positive with 89% analyst buy ratings and an $86 price target, though elevated valuation multiples and execution risks in competitive markets warrant caution. Upside potential exists if earnings growth continues, but investors should monitor margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
